ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2026
Outcome of Non-Hodgkin's Lymphoma in Adults-Real World Experience from a Cancer Centre in North-East India.
Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Non-Hodgkin's lymphoma (NHL) represent diverse subtypes categorized as per immunohistochemical, genetic, molecular and clinical diagnosis delineated by 2016 World Health Organization classification. Given limited real-world data on NHL in North-East India, the objective was to investigate the response and outcome in this cohort. Materials and methods: Demographic, clinical, treatment and response characteristics of 214 NHL patients following frontline immunochemotherapy treated between December 2017 and January 2023 were retrospectively reviewed and analyzed to determine overall survival (OS) and event-free survival (EFS). Results: B cell-NHL accounted for 187 cases, followed by 27 T-NHL. Diffuse large B cell lymphoma (DLBCL) and peripheral T cell lymphoma, not otherwise specified, were the commonest B-NHL and T-NHL, respectively. Bulky disease was seen in 26(12.1%), advanced-stage in 137(64.01%), extra-nodal presentation in 77(35.98%),and grade 2 chemotherapy-related toxicity in 116(54.2%).The overall response rate was 73.36%, with complete response at 63.2% and progression at 20%. Median follow-up was 23 months (interquartile range 15-35 months). The 2-year EFS among those with complete/partial response was 77.7% compared to 24.53% among stable/progression. The 5-year OS was 47.84%. Those with good /low risk international prognostic index (IPI) had a 5-year OS of 62.09% compared to 25.17% among high/poor risk IPI. Most events, Conclusion: Despite treatment barriers, overall response and outcome were non-inferior and comparable to Western data. High-grade DLBCL, T-NHL, advanced stage, poor IPI attributed to suboptimal response and inferior survival, thus emphasizing novel prognostic markers and biological agents based on high-risk molecular signature to enable individualized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.